The Life Sciences team advised Fate Therapeutics on the closing of its public offering of 9,890,000 shares of its common stock, which included 1,290,000 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares.
Fate Therapeutics ;is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.
Priced at $17.50 per share, the gross proceeds of the offering were approximately $173.1 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, the conduct of preclinical research and development, and for general corporate purposes.
The Goodwin team was led by partner Maggie Wong and included counsel Stephanie Philbin, associates Natalie Martirossian, Kyrsten Keith, Allyson Maur and Rachel Thurbon, and senior paralegal Elizabeth Gordon.